文献速递妇科肿瘤

鲁索利替尼联合一线新辅助治疗晚期卵巢癌的I期和随机II期研究:NRG肿瘤学组研究

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
PubMed 文献 · J Clin Oncol · 2024-05-22

该研究在晚期卵巢癌患者中评估JAK1/2抑制剂鲁索利替尼联合标准化疗的新辅助治疗。I期确定最大耐受剂量和II期推荐剂量为鲁索利替尼15 mg口服每日两次;随机II期显示实验组中位无进展生存期14.6个月 vs 参考组11.6个月,HR 0.702(log-rank P=0.059),总生存HR 0.785(P=0.24),作者认为达到主要终点,需进一步研究。

要点

  • I期确定鲁索利替尼联合剂量密集紫杉醇/卡铂的II期推荐剂量为15 mg口服每日两次。
  • 随机II期实验组中位PFS 14.6个月 vs 参考组11.6个月,HR 0.702(log-rank P=0.059)。
  • 实验组3-4级贫血、中性粒细胞减少和血栓栓塞事件有升高趋势,但方案总体耐受良好。

核心结论

  • 鲁索利替尼15 mg口服每日两次联合紫杉醇/卡铂耐受良好、毒性可接受,实验组达到延长PFS的主要终点,需进一步研究。

研究设计与样本

  • I期和随机II期研究,入组拟行新辅助化疗的卵巢/输卵管/原发性腹膜癌患者。
  • I期17例患者接受剂量密集紫杉醇70 mg/m2(第1、8、15天)、卡铂AUC 5(第1天)和鲁索利替尼15 mg口服每日两次(剂量水平1),每21天为一周期,第3周期后行间歇性减瘤术,术后再行3周期化疗/鲁索利替尼,后续鲁索利替尼维持治疗。
  • 随机II期130例患者随机分配至紫杉醇/卡铂联合或不联合鲁索利替尼15 mg口服每日两次治疗3周期,行间歇性减瘤术,术后再行3周期化疗/鲁索利替尼,不再进行鲁索利替尼维持治疗,主要终点为PFS。

主要发现

  • I期确定最大耐受剂量和II期推荐剂量为剂量水平1。
  • 随机II期中位随访24个月,实验组中位PFS 14.6个月 vs 参考组11.6个月,PFS的HR 0.702(log-rank P=0.059)。
  • 总生存HR 0.785(P=0.24)。
  • 实验组3-4级贫血64% vs 参考组27%,3-4级中性粒细胞减少53% vs 37%,血栓栓塞事件12.6% vs 2.4%,实验组有升高趋势。

关键数值与推荐

  • I期推荐II期剂量:鲁索利替尼15 mg口服每日两次,联合剂量密集紫杉醇70 mg/m2(第1、8、15天)和卡铂AUC 5(第1天),每21天为一周期。

临床怎么用

  • 作者认为鲁索利替尼15 mg口服每日两次联合紫杉醇/卡铂耐受良好、毒性可接受,实验组达到延长PFS的主要终点,需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The interleukin-6/Janus kinase (JAK)/signal transducers and activators of transcription 3 axis is a reported driver of chemotherapy resistance. We hypothesized that adding the JAK1/2 inhibitor ruxolitinib to standard chemotherapy would be tolerable and improve progression-free survival (PFS) in patients with ovarian cancer in the upfront setting. MATERIALS AND METHODS: Patients with ovarian/fallopian tube/primary peritoneal carcinoma recommended for neoadjuvant chemotherapy were eligible. In phase I, treatment was initiated with dose-dense paclitaxel (P) 70 mg/m2 once daily on days 1, 8, and 15; carboplatin AUC 5 intravenously day 1; and ruxolitinib 15 mg orally (PO) twice a day, every 21 days (dose level 1). Interval debulking surgery (IDS) was required after cycle 3. Patients then received three additional cycles of chemotherapy/ruxolitinib, followed by maintenance ruxolitinib. In the randomized phase II, patients were randomly assigned to paclitaxel/carboplatin with or without ruxolitinib at 15 mg PO twice a day for three cycles, IDS, followed by another three cycles of chemotherapy/ruxolitinib, without further maintenance ruxolitinib. The primary phase II end point was PFS. RESULTS: Seventeen patients were enrolled in phase I. The maximum tolerated dose and recommended phase II dose were established to be dose level 1. One hundred thirty patients were enrolled in phase II with a median follow-up of 24 months. The regimen was well tolerated, with a trend toward higher grade 3 to 4 anemia (64% v 27%), grade 3 to 4 neutropenia (53% v 37%), and thromboembolic events (12.6% v 2.4%) in the experimental arm. In the randomized phase II, the median PFS in the reference arm was 11.6 versus 14.6 in the experimental, hazard ratio (HR) for PFS was 0.702 (log-rank P = .059). The overall survival HR was 0.785 (P = .24). CONCLUSION: Ruxolitinib 15 mg PO twice a day was well tolerated with acceptable toxicity in combination with paclitaxel/carboplatin chemotherapy. The primary end point of prolongation of PFS was achieved in the experimental arm, warranting further investigation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Landen CN, Buckanovich RJ, Sill MW, et al. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024. PMID: 38776484. doi:10.1200/JCO.23.02076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。